TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37671748

Group type: COMPARATOR
Intervention: avelumab alone (control group)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: avelumab combined with sacituzumab govitecan (anti-Trop-2/topoisomerase inhibitor conjugate)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: avelumab combined with M6223 (anti-TIGIT)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: avelumab combined with NKTR-255 (recombinant human IL-15)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Objective response and duration of response per investigator
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Number of subjects: 252
Study: 37671831

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P)
Number of subjects: 132
Study: 37672016

Group type: EXPERIMENTAL
Intervention: Aripiprazole 2-Month Ready-to-Use 960 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37672083

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPTD) combined with full-mouth disinfection
Number of subjects: 24

Group type: COMPARATOR
Intervention: Full-mouth disinfection (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPTD)
Number of subjects: 24
Study: 37672088

Group type: EXPERIMENTAL
Intervention: Triple uterine tourniquet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single uterine tourniquet
Number of subjects: 60
Study: 37672197

Group type: EXPERIMENTAL
Intervention: Vericiguat 2.5-10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-baseline approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modeled-baseline approach
Number of subjects: 0
Study: 37672268

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg/d for children <35 kg, 160 mg/d for children ≥35 kg, 320 mg/d for adults)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 34
Study: 37672324

Group type: EXPERIMENTAL
Intervention: Pregnancy Remote Monitoring program
Number of subjects: 110
Study: 37672524

Group type: EXPERIMENTAL
Intervention: CaP-TB intervention (facility-based intensified case finding and strengthened household contact management and TPT provision at HIV clinics)
Number of subjects: 146
Study: 37672548

Group type: EXPERIMENTAL
Intervention: Weekly primaquine (PQ8W) at a dose of 0.75 mg/kg for 8 weeks plus dihydroartemisinin piperaquine or chloroquine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Weekly primaquine (PQ8W)
Number of subjects: 50
Study: 37672566

Group type: EXPERIMENTAL
Intervention: Drug-releasing intratumoral microdevices (IMDs) used during tumor resection for 2 to 3 hours.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Drug-releasing intratumoral microdevices (IMDs) used during tumor resection.
Number of subjects: 6
Study: 37672598

Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-General (FACT-G)
Number of subjects: 0
Study: 37672605

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37672694

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg for patients ≥18 years; 15 mg/kg with a 1200 mg cap for patients <18 years) administered intravenously once every 21 days
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 52
Study: 37672868

Group type: EXPERIMENTAL
Intervention: RoVER-mediated redirection of YF-specific CTLs to autologous CD19+ B cells
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: RoVER-mediated redirection of YF-specific CTLs to HIV-1-infected CD4+ T cells
Number of subjects: 51
Study: 37672897

Group type: EXPERIMENTAL
Intervention: DMD-GAS (Gait Assessment Scale for Duchenne Muscular Dystrophy)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: DMD-GAS
Number of subjects: 56
Study: 37673112

Group type: EXPERIMENTAL
Intervention: Radical cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative evaluation and expert surgical management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy followed by surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative protocols
Number of subjects: 0
Study: 37673211

Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 0
Study: 37673430

Group type: EXPERIMENTAL
Intervention: Higher intake of celluloses (E460-E468)
Number of subjects: 95442

Group type: EXPERIMENTAL
Intervention: Higher cellulose E460 intake
Number of subjects: 95442

Group type: EXPERIMENTAL
Intervention: Higher intake of carboxymethylcellulose (E466)
Number of subjects: 95442

Group type: EXPERIMENTAL
Intervention: Higher intakes of monoglycerides and diglycerides of fatty acids (E471 and E472)
Number of subjects: 95442

Group type: EXPERIMENTAL
Intervention: Lactic ester of monoglycerides and diglycerides of fatty acids (E472b)
Number of subjects: 95442

Group type: EXPERIMENTAL
Intervention: Citric acid ester of monoglycerides and diglycerides of fatty acids (E472c)
Number of subjects: 95442

Group type: EXPERIMENTAL
Intervention: High intake of trisodium phosphate (E339)
Number of subjects: 95442
Study: 37673447

Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) for 8 weeks followed by booster sessions for responders
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Mindfulness Practice (MP) for 8 weeks for non-responders
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Positive Aspects of Caregiving Scale
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Engagement in meaningful activities and level of mindfulness
Number of subjects: 272
Study: 37673452

Group type: EXPERIMENTAL
Intervention: Perioperative right ventricular dysfunction (RVD) diagnosed by RV speckle tracking echocardiography
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Days alive and at home at 30 days postoperatively
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) dysfunction
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: T1-cardiovascular magnetic resonance (CMR) imaging preoperatively and postoperatively
Number of subjects: 175
Study: 37673453

Group type: EXPERIMENTAL
Intervention: 7-day course of antibiotic treatment
Number of subjects: 194

Group type: COMPARATOR
Intervention: 14-day course of antibiotic treatment
Number of subjects: 194
Study: 37673642

Group type: EXPERIMENTAL
Intervention: Unilateral focused ultrasound subthalamotomy (FUS-STN)
Number of subjects: 12
Study: 37673858

Group type: EXPERIMENTAL
Intervention: Triplet maintenance therapy (olaparib, pembrolizumab, bevacizumab)
Number of subjects: 44
Study: 37674129

Group type: EXPERIMENTAL
Intervention: Arm-in-arm gait training (intervention group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Side-by-side walking without contact (control group)
Number of subjects: 66
Study: 37674135

Group type: EXPERIMENTAL
Intervention: 14-item Whiteley Index (WI-14)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Illness Attitude Scale (IAS)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: 64-item Health Anxiety Inventory (HAI-64)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: 18-item Health Anxiety Inventory (HAI-18)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Joint factor analysis of WI-14, IAS, HAI-64, HAI-18, and HAI-14
Number of subjects: 423
Study: 37674161

Group type: EXPERIMENTAL
Intervention: Improvement of caregiver mastery over time
Number of subjects: 154
Study: 37674184

Group type: EXPERIMENTAL
Intervention: Relaxation virtual reality intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care offered by public funded maternity services
Number of subjects: 0
Study: 37674205

Group type: EXPERIMENTAL
Intervention: Re-education exercises involving preactivation of the abdominal transverse muscle
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 35
Study: 37674214

Group type: EXPERIMENTAL
Intervention: Flexible outpatient treatment model
Number of subjects: 22
Study: 37674358

Group type: EXPERIMENTAL
Intervention: Plasminogen, human-tvmh (6.6 mg/kg administered every 2-5 days for 48 weeks and every 1-7 days for up to 124 weeks)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Plasminogen, human-tvmh
Number of subjects: 15
Study: 37674384

Group type: EXPERIMENTAL
Intervention: Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pola-R-CHP
Number of subjects: 0
Study: 37674551

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 120
Study: 37674656

Group type: EXPERIMENTAL
Intervention: Online OurRelationship program with full-coach support
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Online OurRelationship program with varying levels of coach support
Number of subjects: 740

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 740
Study: 37674711

Group type: EXPERIMENTAL
Intervention: 30-min daily bright blue-green light (12,000 lux)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dim red light (5 lux)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both interventions (bright blue-green light and dim red light)
Number of subjects: 30
Study: 37674733

Group type: EXPERIMENTAL
Intervention: Specialized telephone counseling
Number of subjects: 577

Group type: COMPARATOR
Intervention: State Quitline referral
Number of subjects: 577
Study: 37674777

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (spinning) for 12 weeks, three times weekly
Number of subjects: 12

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 12
Study: 37674806

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (an ARNi)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan (an ARB)
Number of subjects: 0
Study: 37674871

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR)
Number of subjects: 103
Study: 37674889

Group type: EXPERIMENTAL
Intervention: Gene-based nutrition and lifestyle recommendation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study: 37675038

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) monotherapy
Number of subjects: 184

Group type: COMPARATOR
Intervention: Controlled-release carbamazepine (CBZ-CR) monotherapy
Number of subjects: 184
Study: 37675090

Group type: EXPERIMENTAL
Intervention: Ultrathin-strut biodegradable polymer sirolimus-eluting stents (BP-SES)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Thin-strut durable polymer zotarolimus-eluting stents (DP-ZES)
Number of subjects: 360
Study: 37675355

Group type: EXPERIMENTAL
Intervention: Rituximab combined with plasmapheresis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plasmapheresis alone
Number of subjects: 0
Study: 37675585

Group type: EXPERIMENTAL
Intervention: Aortic stiffness measured by carotid to femoral pulse wave velocity (PWV)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Baseline values of PWV, GLS, PWV/GLS ratio and reservoir left atrial strain
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Lower baseline values of PWV and less impaired GLS and PWV/GLS
Number of subjects: 109
Study: 37675613

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg daily for 180 days
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard-of-care anticoagulation (warfarin or low-molecular-weight heparin) for 180 days
Number of subjects: 55
Study: 37675756

Group type: EXPERIMENTAL
Intervention: Postinfection mucosal IgA concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postvaccination mucosal IgG concentrations
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE2-inhibiting activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infection-induced binding inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postvaccination binding inhibition
Number of subjects: 0
Study: 37675828

Group type: EXPERIMENTAL
Intervention: Treatment for recent HCV infection
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Sustained high probability IDU trajectory
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Sustained high probability chemsex trajectory
Number of subjects: 212
Study: 37675834

Group type: EXPERIMENTAL
Intervention: Secondary distribution of HIV self-tests (HIVST)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard-of-care (SOC; invitation letter to male partner for fast-track testing)
Number of subjects: 500
Study: 37675901

Group type: EXPERIMENTAL
Intervention: HIV-specific cardiovascular risk factors (CRF) - history of AIDS
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: HIV-specific cardiovascular risk factors (CRF) - higher age at diagnosis of HIV infection (per 10 years)
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Higher CD4/CD8 ratio (per standard deviation)
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Longer cumulative duration of antiretroviral therapies
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Longer duration of HIV infection (per 10 years)
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Current smoking (traditional CRF)
Number of subjects: 1243
Study: 37675973

Group type: EXPERIMENTAL
Intervention: ACL-IB
Number of subjects: 29

Group type: COMPARATOR
Intervention: ACL-R
Number of subjects: 29
Study: 37676105

Group type: EXPERIMENTAL
Intervention: SCC-PB+ (short corpus callosum with Probst bundles)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: SCC-PB- (short corpus callosum without Probst bundles)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal CC
Number of subjects: 22
Study: 37676110

Group type: EXPERIMENTAL
Intervention: Apatinib combined with dose-dense paclitaxel and carboplatin (Apa+ddTCb)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Dose-dense paclitaxel plus carboplatin (ddTCb)
Number of subjects: 25
Study: 37676200

Group type: EXPERIMENTAL
Intervention: S-ICD (Subcutaneous Implantable Cardioverter-Defibrillator)
Number of subjects: 1637
Study: 37676209

Group type: EXPERIMENTAL
Intervention: Mechanical wave imaging in healthy subjects
Number of subjects: 76

Group type: COMPARATOR
Intervention: Mechanical wave imaging in patients with severe AS
Number of subjects: 76
Study: 37676259

Group type: EXPERIMENTAL
Intervention: Tremelimumab in combination with durvalumab
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 1171
Study: 37676282

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPI)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 802

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 802
Study: 37676612

Group type: EXPERIMENTAL
Intervention: Posaconazole 300 mg IV/300 mg orally once daily (twice daily on day 1)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Voriconazole 4 mg/kg IV twice daily/200 mg orally twice daily (6 mg/kg on day 1)
Number of subjects: 575
Study: 37676661

Group type: EXPERIMENTAL
Intervention: Cognitive working memory training program (Cogmed software) for 8 weeks (25 sessions)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Standard management (control)
Number of subjects: 169
Study: 37676706

Group type: EXPERIMENTAL
Intervention: Reminiscence based intervention provided by trained young adult volunteers using a digital storytelling platform
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 103
Study: 37676714

Group type: EXPERIMENTAL
Intervention: App-based self-monitoring intervention
Number of subjects: 199

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 199
Study: 37676715

Group type: EXPERIMENTAL
Intervention: Home-based exercise prehabilitation program (details on dosage and duration not available)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based exercise prehabilitation program
Number of subjects: 0
Study: 37676720

Group type: EXPERIMENTAL
Intervention: Personalized risk communication and screening recommendations via a newly designed brochure
Number of subjects: 880

Group type: COMPARATOR
Intervention: Usual brochure of the Vaud CRC screening program
Number of subjects: 880
Study: 37676727

Group type: EXPERIMENTAL
Intervention: Intervention group (8 hours bed rest)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (24 hours bed rest)
Number of subjects: 34
Study: 37676977

Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37677000

Group type: EXPERIMENTAL
Intervention: Melanocortin Pan-Agonist PL9643, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37677076

Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg (LEM10)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 33
Study: 37677111

Group type: EXPERIMENTAL
Intervention: ePRO systems
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Technology Attitude Scale-Adapted
Number of subjects: 210
Study: 37677752

Group type: EXPERIMENTAL
Intervention: Pranayama
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Deep breathing exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 37677894

Group type: EXPERIMENTAL
Intervention: PREMIUM CAT-ACC (computerized adaptive testing tool)
Number of subjects: 496
Study: 37677918

Group type: EXPERIMENTAL
Intervention: Cadonilimab 6 mg/kg intravenously every 2 weeks in cohort A
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cadonilimab 6 mg/kg intravenously every 2 weeks in cohort B
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cadonilimab 6 mg/kg intravenously every 2 weeks in cohort C
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cadonilimab in cohort A
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cadonilimab in cohort B
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cadonilimab in cohort C
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cadonilimab
Number of subjects: 53
Study: 37678215

Group type: EXPERIMENTAL
Intervention: Home-based telerehabilitation group (n = 29)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Home-based paper group (n = 28)
Number of subjects: 54
Study: 37678222

Group type: EXPERIMENTAL
Intervention: Taurolidine/heparin catheter lock solution (13.5 mg/ml taurolidine and 1000 units/ml heparin)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Heparin control catheter lock solution (1000 units/ml)
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Taurolidine/heparin catheter lock solution
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Taurolidine/heparin and Heparin
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Taurolidine/heparin
Number of subjects: 795
Study: 37678233

Group type: EXPERIMENTAL
Intervention: Virtual reality distraction and relaxation (52 patients)
Number of subjects: 106

Group type: COMPARATOR
Intervention: 2-dimensional sham presentations (54 patients)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Virtual reality distraction and relaxation
Number of subjects: 106
Study: 37678236

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (300 mg/1.73 m²)
Number of subjects: 41
Study: 37678257

Group type: EXPERIMENTAL
Intervention: Calpain inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TRPC6 knockdown
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transgenic overexpression of calpastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: TRPC6 overexpression in podocytes (in human kidney biopsies)
Number of subjects: 0
Study: 37678260

Group type: EXPERIMENTAL
Intervention: SCTS
Number of subjects: 569

Group type: COMPARATOR
Intervention: ICS
Number of subjects: 569
Study: 37678274

Group type: EXPERIMENTAL
Intervention: Cefoperazone sodium tazobactam sodium (CSTS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meropenem (MEPM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meropenem plus immunoglobulin (MEPM+IVIG)
Number of subjects: 0
Study: 37678277

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with docetaxel, oxaliplatin, and capecitabine (DOX regimen)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with oxaliplatin plus capecitabine (XELOX regimen)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 300
Study: 37678284

Group type: EXPERIMENTAL
Intervention: AI-IRT system
Number of subjects: 2100
Study: 37678342

Group type: EXPERIMENTAL
Intervention: K-wires exposed above the skin by 2 cm (Group I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: K-wires buried under the skin (Group II)
Number of subjects: 60
Study: 37678374

Group type: EXPERIMENTAL
Intervention: Positive message delivered through audio tape (phase 1)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Standard message delivered through audio tape (phase 1)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Positive message delivered by nurse (phase 2)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Standard message delivered by nurse (phase 2)
Number of subjects: 251
Study: 37678381

Group type: EXPERIMENTAL
Intervention: Medical cardiac group
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Surgical cardiac group
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Noncardiac group
Number of subjects: 1100
Study: 37678447

Group type: EXPERIMENTAL
Intervention: 8-week group tele-exercise program
Number of subjects: 22
Study: 37678574

Group type: EXPERIMENTAL
Intervention: IFN-γ ELISpot assay
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR) model
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: IFN-γ ELISpot incorporated in prediction model
Number of subjects: 393